Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
M Tarsounas, P Sung - Nature Reviews Molecular Cell Biology, 2020 - nature.com
The tumour suppressor breast cancer type 1 susceptibility protein (BRCA1) promotes DNA
double-strand break (DSB) repair by homologous recombination and protects DNA …
double-strand break (DSB) repair by homologous recombination and protects DNA …
Towards precision oncology with patient-derived xenografts
ER Zanella, E Grassi, L Trusolino - Nature Reviews Clinical Oncology, 2022 - nature.com
Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …
mechanisms that make static interrogation of genomic alterations insufficient to guide …
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
MG Rees, B Seashore-Ludlow, JH Cheah… - Nature chemical …, 2016 - nature.com
Abstract Changes in cellular gene expression in response to small-molecule or genetic
perturbations have yielded signatures that can connect unknown mechanisms of action …
perturbations have yielded signatures that can connect unknown mechanisms of action …
Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell …
MC Pietanza, SN Waqar, LM Krug, A Dowlati… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are
active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study …
active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study …
CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics
Abstract CellMiner Cross-Database (CellMinerCDB, discover. nci. nih. gov/cellminercdb)
allows integration and analysis of molecular and pharmacological data within and across …
allows integration and analysis of molecular and pharmacological data within and across …
Biomarker-guided development of DNA repair inhibitors
JM Cleary, AJ Aguirre, GI Shapiro, AD D'Andrea - Molecular cell, 2020 - cell.com
Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
Small cell lung cancer is initially highly responsive to cisplatin and etoposide but in almost
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
every case becomes rapidly chemoresistant, leading to death within 1 year. We modeled …
Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index
S Coats, M Williams, B Kebble, R Dixit, L Tseng… - Clinical Cancer …, 2019 - AACR
Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …
additional antibody–drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle …
Targeting topoisomerase I in the era of precision medicine
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years.
Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage …
Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage …